In February A&R, Penso et al. reported on the results of their study, which explored whether patients with psoriasis, PsA and AS have a higher risk of developing IBD when treated with an IL-17 inhibitor compared with apremilast, a phosphodiesterase 4 (PDE4) inhibitor, or etanercept, a TNF inhibitor.
2017 in Review: Key Findings in Basic Science Highlighted at the ACR/ARHP Annual Meeting
During the ACR/ARHP Annual Meeting, Richard Pope, MD, highlighted some of the top scientific literature on rheumatic disease from 2017. The review session discussed research on the effects of microglia on the central nervous system of SLE patients, the role of adenosine in osteoarthritis and more…
Clinical Trial of Ixekizumab for Psoriatic Arthritis Shows Positive Results
A study found that ixekizumab decreases disease activity and increases physical function in biologic-naive patients with active psoriatic arthritis…
Foundation Researcher Studies Role of IL-17 in Rheumatoid Arthritis
A grant from the American College of Rheumatology (ACR)’s Rheumatology Research Foundation has helped Shiva Shahrara, PhD, conduct research into the molecule, IL-17, that plays a role in recruiting myeloid cells to migrate from the blood to the joint and perpetuating vascularization